



1-28-05

1639 \$
1 fr

PHA 4142.2 (2891/3)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Peter C. Isakson, et al.

Art Unit 1639

Serial No. 10/038,080

Filed January 03, 2002

Confirmation No. 7358

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED
DISORDERS WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A
LEUKOTRIENE B4 RECEPTOR ANTAGONIST

Examiner Jon D. Epperson Ph.D.

January 27, 2005

AMENDMENT F

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,
SIR:

In response to the Office action dated July 27, 2004, please consider the following
remarks.

Amendment to the specification begins on page 2.

Amendments to the Claims begin on page 3.

Remarks begin on page 28.

Conclusion begins on page 42.

02/02/2005 SDENB0B1 00000039 10038080

03 FC:1254 1590.00 OP

02/02/2005 SDENB0B1 00000039 10038080

04 FC:1202 200.00 OP

Amendments to the Specification

Please replace paragraph [0029] (page 8, lines 26-37 and page 9, lines 1-5) with the following paragraph:

Preferred leukotriene B₄ receptor antagonists include Bayer Bay-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, Ono ONO-4057, Terumo TMK-688, Boehringer Ingelheim BI-RM-270, Lilly LY 213024, Lilly LY 264086, Lilly LY 292728, Ono ONO LB457, Pfizer 105696, Purdue Frederick PF 10042, Rhone-Poulenc Rorer RP 66153, SmithKline Beecham SB-201146, SmithKline Beecham SB-201993, Searle SC-53228, Sumitamo SM 15178, American Home Products WAY 121006, Bayer Bay-o-8276, calcitriol, Warner-Lambert CI-987, Merck and Co. L-651392, Lilly LY 210073, Lilly LY 223982, Lilly LY 233569, Lilly LY-255283, Merck and Co. MK-591, ~~Merck and Co. MK-886~~, Ono ONO-LB-448, Purdue Frederick PF-5901, Rhone-Poulenc Rorer RG 14893, Rhone-Poulenc Rorer RP 66364, Rhone-Poulenc Rorer RP 69698, Searle SC-41930, Searle SC-50505, Searle SC-51146, SmithKline Beecham SK&F-104493, and Teijin TEI-1338.